Experiments

Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).

• VHL synthetic lethality screens uncover CBF-β as a negative regulator of STING.

  PMID 41820368 · PMC13121600 · Nature communications · 2026 · 8 claims · 8 setups

  Full-text index only

  CBFB (CBF-β) is a synthetic lethal interactor of VHL in ccRCC cell lines

  786o ccrcc tcga genome-wide competitive immunoblot

• Single-cell epigenetic profiling reveals a tumor-intrinsic interferon response program in ccRCC tied to poor prognosis and BAP1 loss.

  PMID 41719400 · PMC12922754 · Science advances · 2026 · 8 claims · 8 setups

  Full-text index only

  Subclustering of ccRCC tumor cells reveals four shared epigenetic programs (C0-C3) recurrent across patients, cohorts, and disease stages

  rcc internal tumor state-specific single-cell multiome copy

• PBRM1 Deficiency Reshapes an Immune Suppressive Microenvironment Through Epigenetic Tuning of PBRM1-KDM5C-IL6 Axis in ccRCC.

  PMID 41514194 · PMC13042695 · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026 · 8 claims · 8 setups

  Full-text index only

  PBRM1 deficiency increases infiltration of immunosuppressive M2 tumor-associated macrophages (TAMs) and creates an immune-excluded tumor microenvironment

  vhl kidney pbrm1 immunodeficient scrna-seq multiplex crispr-cas9

• HIF sustain a transcriptional regulatory circuit of EPAS1 expression in renal clear cell carcinoma.

  PMID 41714613 · PMC12921326 · Nature communications · 2026 · 8 claims · 8 setups

  Full-text index only

  HIF-2α mRNA is specifically overexpressed in ccRCC tumor tissue/cells compared to normal kidney, while it is reduced in papillary and chromophobe RCC

  erlangen tcga ccrcc tubule qpcr rna-seq rnascope

• Epigenome screening highlights that JMJD6 confers an epigenetic vulnerability and mediates sunitinib sensitivity in renal cell carcinoma.

  PMID 33634984 · PMC7882098 · Clinical and translational medicine · 2021 · 8 claims · 8 setups

  Has reproduction · 85

  JMJD6 is identified as a potent epigenetic vulnerability/fitness gene in RCC by integrating GeCK CRISPR screening data with TCGA-KIRC epigenetic regulator survival analysis

  pan-cancer tcga-kirc rcc balb crispr rna-seq mtt